Advertisement
VRCA vs VRDN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VRCA is a Hold and VRDN is a StrongBuy.
Momentum Indicator for VRCA turns negative, indicating new downward trend
VRCA saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 85 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for VRCA turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 40 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VRCA entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VRCA's RSI Indicator exited the oversold zone, 32 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where VRCA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +10.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in 223 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
VRCA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.080) is normal, around the industry mean (3.035). P/E Ratio (-2.029) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (2.496) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. VRCA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for VRDN turns positive, indicating new upward trend
VRDN saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 68 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for VRDN just turned positive on October 15, 2026. Looking at past instances where VRDN's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
VRDN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRDN advanced for three days, in 212 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for VRDN moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 32 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for VRDN crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRDN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
VRDN broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRDN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.493) is normal, around the industry mean (3.035). P/E Ratio (-6.579) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (30.488) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
VRCA | VRDN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 83 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 83 | 39 | |
P/E GROWTH RATING 1..100 | 13 | 66 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRDN's Valuation (29) in the Biotechnology industry is somewhat better than the same rating for VRCA (82) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew somewhat faster than VRCA’s over the last 12 months.
VRDN's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to VRCA’s over the last 12 months.
VRDN's SMR Rating (98) in the Biotechnology industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to VRCA’s over the last 12 months.
VRDN's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for VRCA (83) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew somewhat faster than VRCA’s over the last 12 months.
VRCA's P/E Growth Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRDN (66) in the Biotechnology industry. This means that VRCA’s stock grew somewhat faster than VRDN’s over the last 12 months.
| VRCA | VRDN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 78% |
| Stochastic ODDS (%) | 3 days ago 82% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 85% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 81% |
| TrendWeek ODDS (%) | 3 days ago 90% | 3 days ago 82% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 83% |
| Advances ODDS (%) | 4 days ago 86% | 5 days ago 82% |
| Declines ODDS (%) | 7 days ago 90% | 3 days ago 83% |
| BollingerBands ODDS (%) | 3 days ago 88% | 3 days ago 79% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
VRCA’s FA Score shows that 1 FA rating(s) are green while VRDN’s FA Score has 1 green FA rating(s).
- VRCA’s FA Score: 1 green, 4 red.
- VRDN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
VRCA’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).
- VRCA’s TA Score: 4 bullish, 4 bearish.
- VRDN’s TA Score: 4 bullish, 6 bearish.
Price Growth
VRCA (@Biotechnology) experienced а -1.81% price change this week, while VRDN (@Biotechnology) price change was +17.55% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
VRCA is expected to report earnings on Nov 13, 2026.
VRDN is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| WISE | 31.76 | 0.50 | +1.61% |
| Themes Generative Artificial Intelligence ETF (WISE) | |||
| DSL | 9.78 | 0.01 | +0.10% |
| DOUBLELINE Income SOLUTIONS FUND | |||
| MHIG | 19.94 | N/A | N/A |
| Milliman Healthcare Inflation Guard ETF (MHIG) | |||
| AFGR | 36.56 | -0.06 | -0.15% |
| First Trust Active Factor Large Cap Growth ETF (AFGR) | |||
| MFUS | 65.33 | -0.48 | -0.73% |
| PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETF (MFUS) | |||
VRDN and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with CYTK. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To VRDN | 1D Price Change % | ||
|---|---|---|---|---|
| VRDN | 100% | -1.97% | ||
| CYTK - VRDN | 42% Loosely correlated | -1.76% | ||
| VCYT - VRDN | 39% Loosely correlated | +4.11% | ||
| RNA - VRDN | 37% Loosely correlated | +0.49% | ||
| VKTX - VRDN | 36% Loosely correlated | -5.54% | ||
| AMLX - VRDN | 36% Loosely correlated | -4.80% | ||
More | ||||